Journal of Hepatology
Volume 50, Issue 4 , Pages 684-692, April 2009

Insulin resistance is not a relevant predictor of sustained virological response to pegylated interferon plus ribavirin in HIV/HCV co-infected patients

  • Nicolás Merchante

      Affiliations

    • Unidad de Enfermedades Infecciosas, Servicio de Medicina Interna, Hospital Universitario de Valme, Sevilla, Spain
    • Grupo Andaluz para el Estudio de las Hepatitis Víricas (HEPAVIR) de la Sociedad Andaluza de Enfermedades Infecciosas (SAEI).
  • ,
  • Ignacio de los Santos-Gil

      Affiliations

    • Servicio de Medicina Interna-Enfermedades Infecciosas, Hospital Universitario de La Princesa, Madrid, Spain
  • ,
  • Dolores Merino

      Affiliations

    • Servicio de Medicina Interna, Hospital Juan Ramón Jiménez, Huelva, Spain
    • Grupo Andaluz para el Estudio de las Hepatitis Víricas (HEPAVIR) de la Sociedad Andaluza de Enfermedades Infecciosas (SAEI).
  • ,
  • Mercedes González-Serrano

      Affiliations

    • Unidad de Enfermedades Infecciosas, Hospital Universitario Virgen de la Victoria, Málaga, Spain
    • Grupo Andaluz para el Estudio de las Hepatitis Víricas (HEPAVIR) de la Sociedad Andaluza de Enfermedades Infecciosas (SAEI).
  • ,
  • José A. Mira

      Affiliations

    • Unidad de Enfermedades Infecciosas, Servicio de Medicina Interna, Hospital Universitario de Valme, Sevilla, Spain
    • Grupo Andaluz para el Estudio de las Hepatitis Víricas (HEPAVIR) de la Sociedad Andaluza de Enfermedades Infecciosas (SAEI).
  • ,
  • Jesús Sanz-Sanz

      Affiliations

    • Servicio de Medicina Interna-Enfermedades Infecciosas, Hospital Universitario de La Princesa, Madrid, Spain
  • ,
  • Elisa Fernández-Fuertes

      Affiliations

    • Servicio de Medicina Interna, Hospital Juan Ramón Jiménez, Huelva, Spain
    • Grupo Andaluz para el Estudio de las Hepatitis Víricas (HEPAVIR) de la Sociedad Andaluza de Enfermedades Infecciosas (SAEI).
  • ,
  • Josefa Ruiz-Morales

      Affiliations

    • Unidad de Enfermedades Infecciosas, Hospital Universitario Virgen de la Victoria, Málaga, Spain
    • Grupo Andaluz para el Estudio de las Hepatitis Víricas (HEPAVIR) de la Sociedad Andaluza de Enfermedades Infecciosas (SAEI).
  • ,
  • José del Valle

      Affiliations

    • Unidad de Enfermedades Infecciosas, Servicio de Medicina Interna, Hospital Universitario de Valme, Sevilla, Spain
    • Grupo Andaluz para el Estudio de las Hepatitis Víricas (HEPAVIR) de la Sociedad Andaluza de Enfermedades Infecciosas (SAEI).
  • ,
  • Juan Macías

      Affiliations

    • Unidad de Enfermedades Infecciosas, Servicio de Medicina Interna, Hospital Universitario de Valme, Sevilla, Spain
    • Grupo Andaluz para el Estudio de las Hepatitis Víricas (HEPAVIR) de la Sociedad Andaluza de Enfermedades Infecciosas (SAEI).
  • ,
  • Antonio Moro

      Affiliations

    • Servicio de Análisis Clínicos, Hospital Universitario de Valme, Sevilla, Spain
  • ,
  • Juan A. Pineda

      Affiliations

    • Unidad de Enfermedades Infecciosas, Hospital Universitario de Valme, Ctra. de Cadiz s/n, 41014 Sevilla, Spain
    • Corresponding Author InformationCorresponding author. Tel.: +34 955015787/+34 955015747; fax: +34 955015747.
    • Grupo Andaluz para el Estudio de las Hepatitis Víricas (HEPAVIR) de la Sociedad Andaluza de Enfermedades Infecciosas (SAEI).

Received 23 September 2008; received in revised form 31 October 2008; accepted 31 October 2008. published online 29 December 2008.

Associate Editor: M.U. Mondelli

Background/Aims

To evaluate the possible influence of baseline insulin resistance in sustained virological response.

Methods

One hundred and fifty-five consecutive individuals from a multicentric cohort of HIV/HCV co-infected patients who underwent therapy with pegylated interferon plus ribavirin were included. The main outcome variable was sustained virological response, defined as undetectable plasma HCV RNA at week 24 after the end of the therapy. Insulin resistance was determined using the HOMA method.

Results

Sustained virological response was achieved in 55 (36%) patients. Forty-two (38%) patients with a HOMA lower than 4 developed sustained virological response vs 13 (29%) of those with a HOMA above 4 (p=0.27). Analyses restricted to patients harbouring genotype 1 or 4 showed similar rates of sustained virological response among patients with a HOMA below and above 4 [19 (27%) vs 7 (24%); p=0.8]. In the multivariate analysis, genotype 3 [AOR 9.26; 95% CI 3.03–28.30; p<0.0001], a baseline HCV viral load below 600.000IU/mL [AOR 2.97; 95% CI 1.03–8.57; p=0.04] and baseline LDL cholesterol above 100mg/dL [AOR 6.62; 95% CI 1.97–22.19; p=0.002] were independently associated with sustained virological response.

Conclusions

Insulin resistance is not a relevant predictor of sustained virological response to pegylated interferon plus ribavirin in HIV/HCV co-infected patients.

Abbreviations: HAART, highly active antiretroviral therapy, HCV, hepatitis C virus, SVR, sustained virological response, IR, insulin resistance, CHC, chronic hepatitis C, ETR, end of treatment response, HOMA, homeostasis model assessment, BMI, body mass index, ALT, alanine-aminotransferase, LDL, low-density lipoprotein, HDL, high-density lipoprotein, AOR, adjusted odds ratio, CI, confidence interval, EVR, early virological response, RVR, rapid virological response

Keywords: HIV/HCV co-infection, HOMA, Insulin resistance, Pegylated interferon, SVR

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 The authors who have taken part in the research of this paper declared that they do not have a relationship with the manufacturers of the drugs involved either in the past or present and they did not receive funding from the manufacturers to carry out their research.

PII: S0168-8278(08)00806-4

doi:10.1016/j.jhep.2008.10.032

Journal of Hepatology
Volume 50, Issue 4 , Pages 684-692, April 2009